CN204882450U - Detection device is united to glycated haemoglobin - blood sugar - Google Patents
Detection device is united to glycated haemoglobin - blood sugar Download PDFInfo
- Publication number
- CN204882450U CN204882450U CN201520477402.0U CN201520477402U CN204882450U CN 204882450 U CN204882450 U CN 204882450U CN 201520477402 U CN201520477402 U CN 201520477402U CN 204882450 U CN204882450 U CN 204882450U
- Authority
- CN
- China
- Prior art keywords
- blood sugar
- glycosylated hemoglobin
- magnetic particle
- detection device
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model relates to the technical field of medical equipment, concretely relates to detection device is united to glycated haemoglobin - blood sugar. The device includes interior arrangement, external device and test paper strip (3), its characterized in that: the interior arrangement includes the biological magnesensor of enzyme, optics magnetic particle component, test paper strip (3) have glucose oxidase's blood sugar detection zone (b) and the glycated haemoglobin detection zone (a) that the peridium has the magnetic particle including the peridium. The utility model provides a detection device is united to glycated haemoglobin - blood sugar catches glycated haemoglobin and blood sugar through the specificity, detects the concentration of glycated haemoglobin and blood sugar simultaneously. Glycated haemoglobin detection zone peridium has the magnetic particle to adsorb glycated haemoglobin, realizes the miniaturization of instrument more easily, and blood sugar detection zone peridium has glucose oxidase, the concentration of sensitive survey play blood sugar fast.
Description
Technical field
The utility model relates to technical field of medical instruments, is specifically related to a kind of glycosylated hemoglobin-blood sugar joint-detection device.
Background technology
Diabetes take persistent high blood sugar as the chronic generalized metabolic disease of one of its basic biochemical character, mainly because insulin secretion in body is absolute or relative deficiency, thus cause a kind of syndrome of the sugar based on carbohydrate metabolism disturbance, protein, fat metabolic disturbance.
That a part of haemoglobin that glycosylated hemoglobin refers in blood and glucose combines.When the concentration of glucose in blood is higher, the saccharification hemoglobin content that human body is formed also can be relatively high.
Using the diagnostic criteria of glycosylated hemoglobin (HbA1c) as diabetes, its detection is subject to clinical great attention just day by day.
Glycosylated hemoglobin saccharification detection method is a lot, the glycosylated hemoglobin detection method applied in current clinical labororatory mainly contains two classes: class methods based on glycosylated hemoglobin and both the non-glycated haemoglobin with electric charge different, as the method such as ion chromatography, electrophoresis; Another kind of method based on the design feature of saccharification group on haemoglobin, as affinity chromatography, Ion capture and immune agglutination method etc.
Glycosylated hemoglobin number proportional with the content of glucose in blood height, indirectly can reflect the change of blood sugar concentration, also reflects the glycometabolic state of body simultaneously.The clinical meaning of glycosylated hemoglobin be mainly reflected in following some:
(1) detection of single blood sugar, glucose in urine, specificly can only reflect blood sugar level during blood drawing, because blood sugar changes to some extent with feed and glycometabolic change, therefore the overall picture of conditions of patients accurately can not be described.And glycosylated hemoglobin changes with change of blood sugar, patient's blood sugar average level of a period of time within 8-12 week before blood test indirectly can be reflected.
(2) the glycosylated hemoglobin < 6.0% of normal person.If during > 9%, illustrate that patient also exists Persistent hyperglycemia, the complication such as diabetic nephropathy, artery sclerosis, cataract can be occurred.Therefore, the clinical blood sugar situation often understanding patient's nearly stage using glycosylated hemoglobin as monitoring index, and generation and the development of assessing chronic complicating diseases of diabetes.
(3) glycosylated hemoglobin not only can be used as the state of illness monitoring index of diabetes, also can be used as the early diagnosis index of " recessiveness " diabetes, type II diabetes, mild.
(4) to the prevention macrosomia of pregnant diabetic women, monster, stillborn foetus, and acute and chronic complication that the supervision of development occurs is significant.
(5) for the not yet clear and definite stupor of the cause of disease or just in glucose infusion rescuer, suddenly the value that glycosylated hemoglobin has antidiastole is looked into.
The concentration of the monistic detection glycosylated hemoglobin of existing device or blood sugar, there are no the device detecting glycosylated hemoglobin and blood sugar concentration simultaneously, and the detection of single index well can not provide the diagnostic message about diabetes.
Utility model content
The utility model needs the problem of prior art solved to be: existing instrument can only the concentration of single detection blood sugar concentration or glycosylated hemoglobin, there are no the device detecting glycosylated hemoglobin and blood sugar concentration simultaneously, the detection of single index well can not provide the diagnostic message about diabetes.
Based on the problems referred to above, the utility model provides a kind of glycosylated hemoglobin-blood sugar joint-detection device, specifically:
The utility model provides a kind of glycosylated hemoglobin-blood sugar joint-detection device, comprise interior arrangement, external device (ED) and test strips 3, wherein, described interior arrangement comprises enzyme biomagnetism sensor, optical magnetic particle cell, and described test strips 3 comprises the blood sugar test district b being coated with glucose oxidase and the glycosylated hemoglobin detection zone a being coated with magnetic particle.
Preferably, described test strips 3 also comprises the quality control region c being coated with glucose oxidase and magnetic particle.
Preferably, described interior arrangement also comprises detecting signal unit, blood sugar test processing unit, glycosylated hemoglobin analytic unit and data storage cell.
Preferably, described detecting signal unit is electrically connected with described enzyme biomagnetism sensor and optical magnetic particle cell.
Preferably, described blood sugar test processing unit and glycosylated hemoglobin analytic unit are electrically connected with described detecting signal unit respectively.
Preferably, described data storage cell is electrically connected with described blood sugar test processing unit and glycosylated hemoglobin analytic unit respectively.
Preferably, described external device (ED) comprises shell 1, display screen 5, on & off switch 6 and prints outlet 4.
Preferably, described display screen 5 is connected with glycosylated hemoglobin analytic unit with described blood sugar test processing unit respectively.
Preferably, described pick-up unit also comprises the test paper groove 2 of the insertion interface as test strips 3.
The beneficial effects of the utility model are: the glycosylated hemoglobin that the utility model provides-blood sugar joint-detection device catches glycosylated hemoglobin and blood sugar by specificity, detect the concentration of glycosylated hemoglobin and blood sugar simultaneously.Glycosylated hemoglobin detection zone is coated with magnetic particle absorption glycosylated hemoglobin, and more easily realize the miniaturization of instrument, blood sugar test district is coated with glucose oxidase, can the concentration determining blood sugar of rapid sensitive.
Below in conjunction with accompanying drawing and each embodiment, the utility model and Advantageous Effects thereof are described in detail, wherein:
Accompanying drawing explanation
Fig. 1 is the structural representation of the glycosylated hemoglobin-blood sugar joint-detection device of the utility model embodiment one.Wherein, 1 is shell, and 2 is test paper groove, and 3 is test strips, and 4 for printing outlet, and 5 is display screen, and 6 is on & off switch, and a is glycosylated hemoglobin detection zone, and b is blood sugar test district, and c is quality control region.
Fig. 2 is the structural representation of the interior arrangement of the glycosylated hemoglobin-blood sugar joint-detection device of the utility model embodiment one.
Embodiment
As mentioned above, the purpose of this utility model is to provide a kind of joint-detection device simultaneously detecting glycosylated hemoglobin and blood sugar, thus the concentration detecting glycosylated hemoglobin and blood sugar of rapid sensitive.
Glucose oxidase energy catalysis glucose oxidase becomes glucolactone, and produces a part hydrogen peroxide, the H of generation
2o
2be diffused into electrode surface, electrooxidation occur, H
2o
2the current signal that electrooxidation produces and H
2o
2concentration is linear, H
2o
2growing amount corresponding with concentration of glucose, therefore quantitatively detect glucose by the size of positive electric current.The magnitude of current that glucose oxidase electrode method is produced by the glucose in measurement blood and the glucose oxidase enzyme reaction in test paper measures blood sugar.Utilize the method to measure glucose, its specificity, accuracy and sensitivity are all higher, and easy and simple to handle, and simultaneously compared to other method, the method is measured faster (within 30 seconds), blood using amount less (below 5 microlitres).
The free amine group of HBB-N terminal Valine forms glycosylated hemoglobin from different carbohydrates glycosylation, magnetic particle is by the surface of glycosylation one end of the absorption glycosylated hemoglobin of the action specificity in magnetic field, glycosylated hemoglobin in blood is enriched in detection zone, determines the content of glycosylated hemoglobin according to the difference of the shot densities of light.
Below in conjunction with the drawings and specific embodiments, the utility model is described in further detail.
Embodiment one
Fig. 1 is the structural representation of the glycosylated hemoglobin-blood sugar joint-detection device of the utility model embodiment one.Wherein this glycosylated hemoglobin-blood sugar joint-detection device, comprise interior arrangement, external device (ED) and test strips 3, described interior arrangement comprises enzyme biomagnetism sensor, optical magnetic particle cell, described test strips 3 comprises blood sugar test district b, glycosylated hemoglobin detection zone a and quality control region c, and described glycosylated hemoglobin detection zone a is coated with magnetic particle.
As glycosylated hemoglobin detection zone a, be coated with magnetic particle suspension, this magnetic particle specificity can catch glycosylated hemoglobin; As blood sugar test district b, this blood sugar test district is coated with glucose oxidase, quantitatively can detect the content of glucose.As quality control region c, be coated with glucose oxidase and magnetic particle suspension simultaneously, its objective is for detect sample and reaction test strips itself and sample loses shape time all no problem.Detect with the quality-control product mixed liquor of blood sugar quality-control product and glycosylated hemoglobin respectively, when result is all out of question, carry out the operation of pattern detection again.
Wherein, described interior arrangement also comprises detecting signal unit, blood sugar test processing unit, glycosylated hemoglobin analytic unit and data storage cell.
Described detecting signal unit is electrically connected with described enzyme biomagnetism sensor and optical magnetic particle cell, described blood sugar test processing unit and glycosylated hemoglobin analytic unit are electrically connected with described detecting signal unit respectively, and described data storage cell is electrically connected with described blood sugar test processing unit and glycosylated hemoglobin analytic unit respectively.
Enzyme biomagnetism sensor is by collecting the magnitude of current glucose in blood and the glucose oxidase enzyme reaction in test paper produced, passed to detecting signal unit, detecting signal unit detects the magnitude of current, current data is delivered blood sugar test processing unit, this unit, by data analysis, is then connected with LCD display, demonstrate the numerical value of blood sugar, be connected with data storage cell simultaneously, by external printing outlet, the blood sugar concentration of mensuration printed.
Described external device (ED) comprises shell 1, display screen 5, on & off switch 6 and prints outlet 4.
Described display screen 5 is connected with glycosylated hemoglobin analytic unit with described blood sugar test processing unit respectively.
Optical magnetic particle cell is by catching the magnetic particle in test strips, this signal is delivered detecting signal unit, detecting signal unit is by detecting the change of magnetic particle, this signal is delivered glycosylated hemoglobin analytic unit, this unit is to after determination data analysis, calculate the concentration of glycosylated hemoglobin, by being connected with display screen, the concentration of glycosylated hemoglobin is shown to user by LED display, can be printed by the determination data of glycosylated hemoglobin by external printing outlet simultaneously.
Described external device (ED) also comprises test paper groove 2, and test paper groove 2, as the insertion interface of test strips 3, fixes the test strips inserting test paper groove by test paper groove two ends bayonet socket.
Wherein glycosylated hemoglobin detection zone a is relative to blood sugar test district b, and the position of distance test paper groove 2 wants far away.Quality control region c is relative to glycosylated hemoglobin detection zone a and blood sugar test district b, and the position of its distance test paper groove 2 is farther.
Utilize the glycosylated hemoglobin-blood sugar joint-detection device of embodiment one, with the glycemic criteria product (2,4 of the different gradients of dilution, 8,16,32 times of dilutions), adopt five point calibration method to do typical curve, compare with quality-control product, the measurement range calculating blood sugar is 0.5 ~ 27.7 mM/l, namely 10 ~ 500 milligrams/deciliter, and wherein said glycemic criteria product and quality-control product are purchased from Omnitest, Germany, concentration is 0.11%.
Utilize the glycosylated hemoglobin-blood sugar joint-detection device of embodiment one, with the glycosylated hemoglobin standard items (2,4 of the different gradients of dilution, 8,16,32 times of dilutions), adopt five point calibration method to do typical curve, compare with quality-control product, the measurement range calculating glycosylated hemoglobin is 1.2% ~ 16%, and wherein glycosylated hemoglobin standard items and quality-control product are purchased from POINTESCIENTIFIC, INC., the U.S., concentration is 11.6%.
Wherein the normal reference value of glycosylated hemoglobin is respectively: 3.80% ~ 5.80%, and whole blood blood sugar normal reference value is 3.9 ~ 6.1 mM/ls on an empty stomach, namely 70 ~ 110 milligrams/deciliter.
Embodiment two
Embodiment two is with the difference of embodiment one, and the glycosylated hemoglobin-blood sugar joint-detection device of embodiment two does not comprise quality control region c.
Embodiment three
Embodiment three is with the difference of embodiment one, and the blood sugar test district b in the glycosylated hemoglobin-blood sugar joint-detection device of embodiment three and the position of a in test strips 3, glycosylated hemoglobin detection zone are exchanged.
The foregoing is only the utility model preferred embodiment, and be not used in limitation the utility model, all make within spirit of the present utility model and principle amendment, equivalent to replace and improvement etc., all need to be included within protection domain of the present utility model.
Claims (4)
1. glycosylated hemoglobin-blood sugar joint-detection device, comprise interior arrangement, external device (ED) and test strips (3), it is characterized in that: described interior arrangement comprises enzyme biomagnetism sensor, optical magnetic particle cell, described test strips (3) comprises blood sugar test district (b) being coated with glucose oxidase and glycosylated hemoglobin detection zone (a) being coated with magnetic particle; Described interior arrangement also comprises detecting signal unit, blood sugar test processing unit, glycosylated hemoglobin analytic unit and data storage cell;
Described detecting signal unit is electrically connected with described enzyme biomagnetism sensor and optical magnetic particle cell;
Described blood sugar test processing unit and glycosylated hemoglobin analytic unit are electrically connected with described detecting signal unit respectively;
Described data storage cell is electrically connected with described blood sugar test processing unit and glycosylated hemoglobin analytic unit respectively;
Described external device (ED) comprises shell (1), display screen (5), on & off switch (6) and prints outlet (4).
2. glycosylated hemoglobin according to claim 1-blood sugar joint-detection device, is characterized in that, described test strips (3) also comprises the quality control region (c) being coated with glucose oxidase and magnetic particle.
3. glycosylated hemoglobin according to claim 1-blood sugar joint-detection device, is characterized in that, described display screen (5) is connected with glycosylated hemoglobin analytic unit with described blood sugar test processing unit respectively.
4., according to the arbitrary described glycosylated hemoglobin-blood sugar joint-detection device of claim 1-3, it is characterized in that, described pick-up unit also comprises the test paper groove (2) as the insertion interface of test strips (3).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520477402.0U CN204882450U (en) | 2015-07-03 | 2015-07-03 | Detection device is united to glycated haemoglobin - blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520477402.0U CN204882450U (en) | 2015-07-03 | 2015-07-03 | Detection device is united to glycated haemoglobin - blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204882450U true CN204882450U (en) | 2015-12-16 |
Family
ID=54826811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520477402.0U Active CN204882450U (en) | 2015-07-03 | 2015-07-03 | Detection device is united to glycated haemoglobin - blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204882450U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106353513A (en) * | 2016-08-31 | 2017-01-25 | 基蛋生物科技股份有限公司 | Glycosylated hemoglobin/blood sugar integrated detection bigeminy strip and preparation method thereof |
| CN107436318A (en) * | 2017-08-17 | 2017-12-05 | 武汉璟泓万方堂医药科技股份有限公司 | A kind of electrochemistry blood testing and device for reducing red blood cell interference |
| CN114660137A (en) * | 2022-03-25 | 2022-06-24 | 智享生物(苏州)有限公司 | Novel automatic glucose detecting instrument |
-
2015
- 2015-07-03 CN CN201520477402.0U patent/CN204882450U/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106353513A (en) * | 2016-08-31 | 2017-01-25 | 基蛋生物科技股份有限公司 | Glycosylated hemoglobin/blood sugar integrated detection bigeminy strip and preparation method thereof |
| CN107436318A (en) * | 2017-08-17 | 2017-12-05 | 武汉璟泓万方堂医药科技股份有限公司 | A kind of electrochemistry blood testing and device for reducing red blood cell interference |
| CN114660137A (en) * | 2022-03-25 | 2022-06-24 | 智享生物(苏州)有限公司 | Novel automatic glucose detecting instrument |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dungan et al. | Glucose measurement: confounding issues in setting targets for inpatient management | |
| Clarke et al. | A history of blood glucose meters and their role in self-monitoring of diabetes mellitus | |
| Feldman et al. | FreeStyle™: a small-volume electrochemical glucose sensor for home blood glucose testing | |
| JP3337670B2 (en) | Specimen for analyzing body fluid samples and reading with a detector | |
| Yamaguchi et al. | Noninvasively measuring blood glucose using saliva | |
| US4397956A (en) | Means for monitoring the status of control of ketoacidosis-prone diabetics | |
| Bloomgarden | A1C: recommendations, debates, and questions | |
| CN108392210A (en) | Automatic blood sampling detects and dismountable blood glucose meter | |
| Smaldone | Glycemic control and hemoglobinopathy: when A1C may not be reliable | |
| CN204882450U (en) | Detection device is united to glycated haemoglobin - blood sugar | |
| Lundholm et al. | Applications and pitfalls of hemoglobin A1C and alternative methods of glycemic monitoring | |
| Wiener | Whole blood glucose: what are we actually measuring? | |
| Burritt | Current analytical approaches to measuring blood analytes | |
| Bodington et al. | Point-of-care testing technologies for the home in chronic kidney disease: a narrative review | |
| Wang et al. | Annual biological variation and personalized reference intervals of clinical chemistry and hematology analytes | |
| Torjman et al. | Accuracy of the hemocue portable glucose analyzer in a large nonhomogeneous population | |
| Su et al. | Comparative Agreement Analysis of Differences in 1, 5‐Anhydroglucitol, Glycated Albumin, and Glycated Hemoglobin A1c Levels between Fasting and Postprandial States in Steamed Bread Meal Test | |
| WO2017012191A1 (en) | Human blood sugar level detection method | |
| Fajrin et al. | Development of Diabetes Detection Equipment Using TCS3200 and PH SKU: SEN0161 Sensors | |
| CN107941722B (en) | Blood sample analysis and test system | |
| Raza et al. | 100 years of glucose monitoring in diabetes management | |
| CN111521829B (en) | Glycosylated hemoglobin test paper and glycosylated hemoglobin detection method thereof | |
| CN204666641U (en) | Small-sized glycosylated hemoglobin instrument | |
| CN103424552A (en) | Test card for detecting human glycated albumin | |
| Suresh Babu et al. | Comparing the glucose values by glucometer and laboratory methods in the diagnosis of gestational diabetes mellitus: A hospital based study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |